Heading: Combat chikungunya with confidence – explore Biosynth’s CHIKV antigen and antibodies

Body:

Over 240,000 cases and 90 deaths due to Chikungunya virus (CHIKV) have been reported globally in the first half of 2025 alone – and the numbers are growing.

With outbreaks expanding into Europe, Asia, Africa, and the Americas, the need for accurate and rapid diagnostics is more critical than ever.

At Biosynth, we’re equipping researchers and diagnostic developers with high-quality CHIKV antigens and antibodies designed for next-generation assays.

Our CHIKV Reagent Portfolio Includes:

· Recombinant CHIKV E1 Antigen (A226V mutant) – targets the key mutation enabling spread via Aedes albopictus

· Envelope 1 & 2 Antigen Mouse Monoclonal Antibodies – 2 clones

· Envelope 1 Antigen Mouse Monoclonal Antibodies – 5 clones

· Envelope 2 Antigen Mouse Monoclonal Antibody

Whether you're building ELISAs, immunofluorescence assays, or rapid diagnostic testing platforms, our reagents deliver reliable performance and batch consistency.

Ready to Accelerate Your CHIKV Diagnostics?

Explore our full range of reagents for IVD today.

Visit Our Diagnostics Reagents Page     

Read our blog for more information on Chikungunya virus